• Maven Capital Partners backed a £1.3 million follow-on funding round for Magnitude Biosciences, a Durham University spinout based at NETPark.
• Magnitude is developing VivoScan, a high-throughput drug screening platform using C. elegans worms, imaging, machine learning, automation, robotics.
• Proceeds earmarked to scale the screening platform, expand commercial activity with global pharma clients, add equipment, hire staff.
• Maven previously invested in Magnitude in May last year through NPIF II - Maven Equity Finance, alongside the Finance Durham Fund.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maven Capital Partners UK LLP published the original content used to generate this news brief on September 18, 2026, and is solely responsible for the information contained therein.